Today's News
Access Pharmaceuticals, Inc. Provides an Update on Polymer Platinate
AP5346
- Significantly Greater Tumor DNA-Platinum Complexes Formed
Compared With
Oxaliplatin -

- Second US Patent Granted -

DALLAS, Feb. 5 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS,
INC.
(Amex: AKC) today provided an update on the status of its AP5346
Polymer
Platinate Program, including the patent status, preclinical data and
the
progress of the Phase I clinical trial.
The AP5346 program is designed to selectively deliver DACH
platinum to
tumors by capitalizing on the biological differences in the
permeability of
blood vessels at tumor sites versus normal tissue. This is achieved
by
attaching the DACH platinum compound to a polymer, which enhances
tumor
exposure to the drug while minimizing the interaction of the
chemotherapeutic
agent with normal cells, thereby reducing the side-effects of
therapy. In
addition, the attachment of DACH platinum to the polymer appreciably
extends
the time that DACH platinum remains in circulation in the blood
stream,
further increasing exposure of the tumor to the drug.

Preclinical Results
Preclinical studies of the delivery of platinum to tumors and to
tumor
DNA, which is the main target for anti-cancer platinum agents, have
recently
been completed. These studies, conducted in a B16 melanoma tumor
model,
compared AP5346 with oxaliplatin at equitoxic doses. Compared with
oxaliplatin, AP5346 demonstrated:
-- In excess of 14 times more platinum was delivered to the
tumor
-- In excess of 10 times more platinum tumor DNA complexes were
formed
-- The initial concentration of DNA complexes were higher and
increased
over a 5-day period.

Compared to oxaliplatin, AP5346 forms a much greater number of
tumor DNA
complexes, and continues to generate these complexes for a longer
period.
These preclinical results support the previously reported data from
tumor
growth inhibition studies conducted in the B16 and other tumor
models, which
showed that AP5346 is superior to oxaliplatin in inhibiting growth of
the
tumor.
Commenting on the study results, Kerry P. Gray, President and CEO
of
Access stated, "These exciting data further strengthens the
preclinical
package that has been developed for AP5346. Demonstrating that
significantly
greater amounts of platinum are being delivered to the target site to
inhibit
tumor growth is a very positive preclinical demonstration that the
polymer
therapeutics approach for platinum delivery can achieve the projected
benefits

Put "polymer platinate ap5346" into www.google.com (without quotes)
for more refs.

Best,
Ed